text:
Valve's digital rights management services as well as the biggest online store, Steam, has gone through countless changes over the years. Starting as a seemingly unnecessary and very buggy application that frustrated the early adopters, it quickly grew to be the mecca of independent game developers thanks to the Greenlight system, only to become an almost unmanageable waterfall of endless new releases, including unfinished or downright broken titles. Many gamers and journalists cried for a better way to filter the onslaught of games. Valve has just issued a new major update to alleviate that, but perhaps the new homepage has a bit too much curation.
The latest update does away with the tedious, tabbed "carousel" view of new releases, introducing a simple list of popular new or upcoming titles. It seems like the not-yet-popular titles might not make it to the front page as easily. What is an even bigger change, however, is the extensive list of recommendations tailored to each individual gamer. The explorer queue features "the new, popular, and top-selling releases on Steam," showing games one recommended title at a time. Scrolling below the main store page leads to an endlessly-refreshing listing of games based on the user's playtimes, favorite genres, wishlist, friend recommendations and so on.
While the update seems great at first glance, as Rock Paper Shotgun reported, it instantly introduces a problem. All the games displayed on the front page are either "popular" new releases, or games only similar to the titles the users have already played. This means that small indie developers who have not lucked out with marketing savvy could be easily overlooked. Gamers themselves are less likely to broaden their horizons as well, being exposed to recommended games that are ultimately more of the same and leading to a self-reinforcing loop. With so many new releases each day, discovery of smaller indies has already been a problem in the past, and the latest update only makes it even harder. The detailed preference-based list is undoubtedly a great addition by itself, but combined only with the showcase of the already-popular titles, it introduces too much skewed curation on the Steam homepage.
Luckily, there is another great addition in this update. Valve has introduced the idea of Curators, or influential people and organizations others can follow for gaming recommendations. The popular YouTube figure Total Biscuit or gaming sites like Rock Paper Shotgun and Eurogamer can already be followed, together with many other prominent figures. However, if psychology has taught the world anything, consumers ought to be most likely to follow those reviewers whose opinions they agree with most. While the choice is ultimately on the consumer side, the Curator system could lead to similar discoverability limitations as the tailoring the presented games based on personal preferences.
There is no doubt Steam needs a better way of filtering its exponentially growing catalog. The store had already released more games by May of 2014 than in all of 2013, and the number only keeps growing. Sure, gamers still have the advance search, tags, outside gaming reviewers and magazines, as well as friends they can use to find new titles outside of their current gaming preferences.
However, the burden of informed search is entirely on their shoulders, so it is no surprise many simply turn to checking the storefront for new ideas. Indie developers in the past have explained how getting onto Steam and securing that front page spot has had a dramatic impact on their sales and discoverability. With the new design limited to just the most popular titles as well as personal preferences, it will only get harder for smaller studios to get discovered. Perhaps this time around, the new Steam homepage curates a little bit too well.
By Jakub Kasztalski
Rock Paper Shotgun


text:
Stress May Increase The Risk Of Sun Induced Skin CancerDec 30, 2004Mice were exposed to ultraviolet B radiation, the type of solar radiation that causes sunburn and skin cancer. A group of these mice were then exposed to the smell of fox urine to induce stress,foxes are a natural mouse predator. Exposure to fox urine started 14 days beore ultraviolet B radiation and was continued 3 times a week for the duration of the study.
Green Tea's EGCG May Fight MelanomaDec 24, 2004Melanoma accounts for only 4% of all skin cancers, but most of the skin cancer related deaths. Standard systemic therapies are inadequately effective therefore novel approaches are needed. Naturally occuring substances in beverages and foods has shown benefit in a number of cancers and nonmelanoma skin cancers.
Magnesium and Vitamin B6 Reduce Hyperexcitability in ChildrenDec 23, 2004Magnesium and vitamin B6 are involved in numerous important activities in the body including the creation of important neurotransmitters in the brain. If you lack magnesium your bones are affected, you can become depressed, or suffer from nervousness and anxiety, insomnia, cardiac arrythmias, and high blood pressure. Normally clinicians check the level of magnesium by looking at its concentration in the plasma.
Genistein Inhibits the Breakdown of BoneDec 21, 2004< The breakdown of bone is triggered by osteoclast cells - large cells in the bone marrow. Osteoclasts are actually a type of immune system cell called a macrophage. When the immune system releases a chemical messenger known as Interleukin-1beta (IL-1beta), the IL-1beta signals the osteoclasts to breakdown bone.
Body Seems To Have Ability To Keep A Dormant Cancer In CheckDec 20, 2004Researchers at the University of Texas Southwestern in Dallas collected blood from 36 breast cancer patients who had survived for at least 7 years, some of these patients had mastectomies 20 years prior. One-third of these former patients were found to have breast cancer cells floating in their blood stream. The women who had a mastectomy may have a low rate of cancer recurrence, but after about 20 years the risk of recurrence rises suddenly to about 20% - this is called dormancy.

subset: commoncrawl


text:
register f
Budjetti €8-30 EUR
Hello, i have a login form that takes data from mysql database, it works well, all fields are displayed on the file after register file, except 1. I use code swift with php. Can someone check why i dont get this field to other file?
Myönnetty käyttäjälle:
hello sir, please share you detail. Relevant Skills and Experience swift, php Proposed Milestones €12 EUR - before start
24 freelanceria on tarjonnut keskimäärin %project_bid_stats_avg_sub_26% %project_currencyDetails_sign_sub_27% tähän työhön
Hello, We are web experts team and fix your input field [login to view URL] share page url to check the process and issue now . Please check our latest Portfolio :- 1. [login to view URL] 2. http://genesisbirthphotogra Lisää
Hi, You can find our Portfolio : [login to view URL] Relevant Skills and Experience Reason for giving me this work 1. Have experience of 4+ year 2. On time delivery 3. Submit wo Lisää
I have read all your requirements and find them best suitable to my profile. I have all the expertise required to incorporate all the features required in your websites. Relevant Skills and Experience I am a WordPress Lisää
Hi Greetings, I read your job description very-well and ready to start work from now. my abilities would be perfect for your venture and i can finish this job within the necessary time frame. Relevant Skills and Ex Lisää
Hi Greeting, I read your requirements and understand very-well and ready to start work from now. Let's discuss more in chat, waiting for your reply. Portfolio:- [login to view URL] Relevant Skills and E Lisää
Let me check it, send me the file. Rocky Stay tuned, I'm still working on this proposal.
hello, I am expert in php so I am one of the suitable candidate for this project. feel free to contact me. Relevant Skills and Experience php Proposed Milestones €20 EUR - done
I'm interested in your project. Please send me a message so that we can discuss more. Relevant Skills and Experience I'm available to discuss more on your project, I will provide 24/7 support and quick response guaran Lisää
Dear Sir, i can correct your script. i can find why fields not getting on file. please [login to view URL] waiting for your reply am expert in PHP Relevant Skills and Experience PHP,MYSQL,AJAX,HTML Proposed Milestones Lisää
We have 10 years of experience in IT but new to freelancing site & owned by AUSTRALIAN company. We have basic understanding of your requirement & would love to discuss your project scope in detail. Relevant Skills and Lisää
i read it cana you pl let me know where do you need your data i will get it done right away looking forward for the reply to shake of more clarity Relevant Skills and Experience php ,javascript,json,html,mysql Propos Lisää
Hello, i have read the project description very carefully. Ready to start work now and we will complete your project on your turnaround time. Looking forward for the response Thanks Relevant Skills and Experience PHP, Lisää


text:
Curators of Souls - PDF
"It is the year 1962, and finished the Age of Leo, which" "remained for a period of two millennia. For approximately the last hundred years was that, many babies were born or dubbed Indigo children's future. These fantastic children began to rise as we know in large quantities due to the need that existed at the time of evolution as a species. As such the mission that brought initially was to help in the reform of all existing systems in Social and Educational Humanity."
This is only a PDF preview of first few pages of Curators of Souls by José Cruz. Please download the full version to read the complete book.
Note: You must have Adobe Reader or Acrobat Installed to see this Preview
Note: You must have Adobe Reader or Acrobat Installed to see this Preview


text:
This website of the Community Development Advisory Committee (CDAC) is designed to gain citizen input on implementing the Strategic Plan for Community Development, reinvestment planning, coordinating city resources, and leveraging private sector investment within San Antonio.
The CDAC's role is to build relationships with community partners, propose policy changes regarding community development, and make recommendations to the City Council. There are 11 positions available in the following categories:School District Public Transit College & University Neighborhood Association Workforce Development and Capacity Building Small Business Assistance Environment Non-Profit Developer/Service Provider Real Estate/Development Financial Services Non-Profit Housing Provider
To see the current list of CDAC members, please click here.
Citizens interested in one of the above positions may obtain an application from the Office of the City Clerk located on the 2nd floor of City Hall, 100 Military Plaza, or apply on-line by clicking here.
If applying online, please ensure you select the correct board application for which you are applying. The deadline to submit an application is Friday, November 14. Applications may also be mailed to the address below or faxed to (210) 207-7032. For more information on the City Boards, please click here or call (210) 207-7253.Mailing Address: Office of the City Clerk Attn: Boards and Commissions P. O. Box 839966 San Antonio, Texas 78283-3966
Press Clippings
Filed under: Uncategorized | Leave a comment »


text:
Anne has ruled out Brown Bear because it is too cumbersome and work intensive. The group will be testing Zimbra's open source product and another solution from Sun One. It was agreed that PCWG will also extend an invitation to OIT to come and speak about their product and costs associated with use for the November or December meeting.
Grace Agnew forwarded John her Action Plan for the group after the meeting and we will discuss that at the next meeting.
November 17, 10:00 a.m. -12:00p.m. (Recorder: K. Kuehl…K. McGuire…A. Ruggiero)


text:
Planning Your College Campus Visits
The campus visit is one of the most valuable informational tools at your disposal. It can serve to motivate and engage younger students and help older ones determine which schools are a good fit. There's really no substitute for first-hand experience. After all, this is where four years and lots of dough will be spent – it's smart to be an educated consumer!
Freshman/Sophomore Year:
Use preliminary campus visits to motivate and engage your student. Seeing the colleges gives them the perspective that there really is "life after high school," and it's worth working for. Check out campuses close to home or visit a few while away on a family vacation or business trip. It doesn't matter if the schools have appeal or not – you're just doing preliminary research in order to become educated consumers. Look at small and large schools in rural and urban settings to get an idea of what setting/size scenario feels right.
Junior Year:
Now it's time to get down to business. If you can, visit every school on the wish list. Take the tour, go to the info sessions, and schedule an interview, if possible. Stay overnight in the area and take in the scene. Walk around; eat at a local hang out, do something fun. Read the newspaper, watch local television, and talk to the natives about living there. Be sure to take notes so that you can compare your insights at a later date.
Senior Year:
Once the acceptance letters come in, arrange an overnight visit to the top two schools during the week, while classes are in session. Your teen should stay in the dorms, attend classes, immerse her in campus life, and investigate areas of interest. Talk to as many students and teachers as possible about their experience at the school. This is also a good time to check out internship and community service opportunities available in the area.


text:
Heron International, owned by Gerald Ronson, has submitted the planning permission for the much anticipated Heron Plaza development scheme.
The scheme, worth £500 million will sit in the heart of the City of London, near to Liverpool Street Station. It is the second and final phase of works by the adjacent Heron Tower.
It will contain the first purpose built luxury hotel in City for 30 years, as well as residential and a substantial amount of office space. The tower will be 43-storeys high, comprising around 190 hotel suites, 120 residences, gym, spa, swimming pool and events space. There will also be an unconfirmed amount of prime office space at the location.
"This genuine mixed use centre will be a model for sustainable urban development in the capital. It will create a new public open space, scarce and highly valued in a densely built part of the City…(it will) reflect London's status as the financial capital of the world and support the City's core mission as a centre for business and excellence," commented Gerald Ronson.
New developments are finally starting to emerge again following the financial crisis, and mixed use sites such as this will be genuinely and enthusiastically received. Not only is there a need for prime office space but also space for new office users to live and entertain clients.


text:
All orders placed before 14:00 will be shipped today | Worldwide shipping
You know what they say; when wearing a bow doors open for you! Following the choker trend, we saw the choker bowtie trend make a comeback and we believe it is here to stay. Wear your choker bowtie with a feminine blouse or a cute dress like a real Parisienne of combine it with a tough denim jacket and a basic t-shirt like a real tomboy.
PiNNED by K's choker bowties are a real eye-catcher and perfect to accessorise with our candy badges!
Product information:
The choker bowtie easily closes through a bowtie closure. Our choker bowties are made of 100% cotton. The chocker bowties are 16.5cm wide and 13.5cm long and adjustable in size.


text:
Rigils Bungalows and spa offers peaceful accommodation in Lembongan, a 5-minute walk from Tamarind Beach. It has an outdoor pool, and a restaurant.
The spacious lodgings at Lembongan Rigils feature open-concept bathrooms and traditional décor. Rooms come with fans and mosquito nets.
Guests can lounge by the outdoor pool or indulge in relaxing massage services at the spa. Fishing and snorkelling trips can be arranged at the tour desk.
Rigils Lembongan Bungalows is a 25-minute boat ride from Sa...nur Beach.
|Tamarind Beach no.4


text:
Rajkot: Riding on a superb all-round performance by Ravindra Jadeja, Saurashtra have taken a first innings against Jharkhand on the first day of their Group C Ranji Trophy match here.
After bundling out Jharkhand for a meagre 168, Saurashtra scored 205 to take a slender 37-run lead in the first innings at stumps on day one.
Electing to bat, Jharkhand kept losing wickets at regular interval as Jadeja wreaked havoc, taking six wickets for 71, while Kamlesh Makvana (4/46) also chipped in with four scalps.
Opener Ishan Kishan top scored with 87 but only three other batsmen could reach the double-digit mark.
Replying to Jharkhand's total, Saurashtra also did not have a good start and they also failed to apply themselves.
But thanks to Jadeja's 75-ball 58, the home team managed to take a slight edge over their opponents.
For Jharkhand, Shahbaz Nadeem claimed four for 38.
Brief scores:
Jharkhand 1st innings: 168 all out (Ishan Kishan 87, Ravindra Jadeja 6/71, Kamlesh Makvana 4/46).
Saurashtra 1st innings: 205 all out (Ravindra Jadeja 58, Cheteshwar Pujara 27; Shahbaz Nadeem 4/38).


text:
An expected decision by the General Assembly to raise state vehicle fees would jump-start four stalled county road projects, including anoverpass for Route 103 that would improve traffic flow on U.S. 29, astate transportation department spokeswoman said.
Legislators will vote June 26 on 60 fee increases that would generate more than $40 million a year for the state Transportation Trust Fund.
A sharp drop in fee revenues, mainly on new car purchases, put most new state transportation projects on hold in December.


text:
- Virginia Warner
- 3 years ago
- Views:
2 WHO Drug Information WHO Drug Information provides an overview of topics relating to drug development and regulation that are of Current relevance and importance, and will include the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). Its contents reflect, but do not present, WHO policies and activities and they embrace socioeconomic as well as technical matters. The objective is to bring issues that are of primary concern to drug regulators and pharmaceutical manufacturers to the attention of a wide audience of health professionals and policy-makers concerned with the rational use of drugs. In effect, the journal seeks to relate regulatory activity to therapeutic practice. It also aims to proivde an open forum for debate. Invited contributions will portray a variety of viewpoints on matters of general policy with the aim of stimulating discussion not only in these columns but wherever relevant decisions on this subject have to be taken. WHO Drug Information is published 4 times a year in English and French. Annual subscription: Sw. fr. 50. Airmail rate: Sw. fr. 60. Price per copy: Sw. fr. 15. World Health Organization 1989 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation, in part or in toto, application should be made to: Chief, Office of Publications, World Health Organization, 1211 Geneva 27, Switzerland. The World Health Organization welcomes such applications. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Authors alone are responsible for views expressed in signed contributions. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. ISSN
3 Volume 3, Number 3, 1989 World Health Organization, Geneva WHO Drug Information Contents General Policy Topics WHO Certification Scheme on the Quality of Pharmaceutical Products moving in International Commerce: Guidelines for Use Reports on Individual Drugs Rifampicin and venous thrombosis Minimizing steroid requirements in asthmatics Induced resistance to zidovudine Interferon alfa: a role in HIV infection? Dipyrimadole: a place in the management of HIV infection? Ciclosporin and atherosclerosis Is chloroquine resistance in falciparum malaria reversible? Chloramphenicol-induced aplastic anaemia: confusing evidence Carbamazepine: evidence of teratogenic potential Acetylsalicylic acid and coronary disease: benefits and risks AIDS vaccines: are the prospects improving? General Information Antibiotic-resistant pneumococci: disturbing trends Food-based oral rehydration preparations Labelling errors: GMP changes contemplated Postmenopausal hormone replacement: is there really a cancer risk? Erythromycin resistance in Streptococcus pyogenes Folate supplements and neural tube defects Contrast media: the risk of nephropathy Oral contraceptives and breast cancer Anti-leukaemic therapy: a need for tang-term assessment Bioengineering: new therapeutic perspectives Good Manufacturing Practices: a catalogue of shortcomings Exports from Europe: a turn of the screw Hypolipidaemic agents: who should receive them? Regulatory Matters Dideoxyinosine: a promising anti-hiv agent Bovine brain gangliosides: interim suspension Buprenorphine: increasing diversion Chlorofluorocarbons: limitations on use Diagnostic test for HIV infection Exifone: interim suspension Disclosure of inactive ingredients Recombinant erythropoietin (INN epoetin alfa) Radiocontrast media: labelling changes Tegafur and leukoencephalopathy Tiopronin and liver damage Advisory Notices Contact lenses: risk of keratitis Mefloquine: acute neurological reactions Human T-lymphotropic virus: screening of blood products Essential Drugs Leishmaniasis Meglumine antimoniate/sodium stibogluconate Pentamidine Amphotericin B Newly Registered Products Recent publications Scientific basis of fertility regulation: safety requirements for contraceptive steroids Medicines in pregnancy Drugs used in anaesthesia Recommended International Nonproprietary Names: List
5 WHO Drug Information Vol. 3, No. 3, 1989 General Policy Topics WHO Certification Scheme on the Quality of Pharmaceutical Products moving in International Commerce: Guidelines for Use Provisions and objectives Pharmaceutical substances are biologically active and they share, in varying degree, a potential to induce unwanted as well as beneficial effects. The risk of serious unwanted reactions and also of therapeutic failure are accentuated when products are either substandard in quality or administered incorrectly. Manufacturers consequently need to produce and package their products in accordance with accepted norms, referred to widely as "good manufacturing practices" (GMP), and to assure their correct use by furnishing adequate reliable information to both prescribers and consumers. Various codes of GMP have been developed, both at national and at international level, to cover every aspect of the production of finished pharmaceutical products. These establish norms for the qualifications and experience of the responsible personnel, the layout and amenities of production and storage areas, sanitation, maintenance of equipment, verification of starting materials, supervision of manufacturing operations, in-process quality controls, documentation, and labelling and packaging. Implementation of these practices by the manufacturer provides assurance that each batch of every product has been made from materials of the required quality; that it complies with the labelled pharmacopoeial specification; that it is adequately packaged and labelled; and that it will remain stable and adequately bioavailable throughout its labelled shelf-life under specified storage conditions. Whereas certain governments and large independent drug procurement agencies are able to commission a full analysis of samples of each imported consignment of pharmaceutical products and active drug substances, such safeguards are beyond the resources of most countries. Still less can they verify labelled claims regarding stability and bioavailability. Even when independent analyses can be undertaken, their limitations must be appreciated. For instance, impurities irrelevant to an established pharmcopoeial monograph, but generated when a substance is produced using a novel route of synthesis, might escape detection in the prescribed analyses. A comprehensive system of quality assurance must consequently be founded, not only on a reliable system of licensing and when practicable independent analysis of the finished product, but also upon assurance, obtained through independent inspection, that all manufacturing operations are carried out in conformity with the requirements of GMP. Transnational commerce in pharmaceutical products would be greatly facilitated if all inspections were conducted in accordance with internationallyrespected standards. To provide an administrative basis for reciprocal recognition of the findings and decisions of their respective inspectorates, a number of highly-evolved national drug regulatory authorities founded the Pharmaceutical Inspection Convention under the aegis of the European Free Trade Association in Similar understandings have been developed between the Member States of the Council for Mutual Economic Assistance, and those of the Association of South-East Asian Nations. Mutual recognition is the outcome of bilateral understandings between collaborating countries. If international trade in pharmaceuticals is to be facilitated in a global context, multilateral understandings are also necessary. Thus, recognizing the need to establish norms for GMP which any Member State is free to adopt and apply, the World Health Assembly endorsed the first version of the WHO Good Manufacturing Practices Text and WHO Certification Scheme on the Quality of Pharmaceutical Products moving in International Commerce in The Scheme, which was extensively amended in 1975, is an administrative instrument through which each participating Member State undertakes, upon application by the product licence-
6 General Policy Topics WHO Drug Information Vol. 3, No. 3, 1989 holder, to provide to the competent authority of another participating Member State an attestation on whether: a specific product is authorized for sale or distribution within the exporting Member State; and the plant in which it is produced is subject to inspections at suitabe intervals to establish that the manufacturer conforms to WHO's recommendations for GMP. In 1988, the Scheme was re-examined following recognition that more widespread and rigorous use of its provisions offers a mechanism not only of controlling legitimate trade in pharmaceutical products but of combating illicit trade in falsely labelled, counterfeited or substandard goods. It was further decided to bring within its ambit: not only finished dosage forms of products intended for human administration but, additionally: dosage forms of veterinary products administered to food-producing animals and also those starting materials that are subject to control by legislation in the exporting Member State. all approved information and/or labelling included in packaging materials and package inserts supplied with these products in the country of export, together with the dates on which relevant approvals were accorded. Eligibility for participation Any Member State intending to participate in the Scheme may do so by informing the Director- General of the World Health Organization, in writing, of: its willingness to participate in the Scheme together with any significant reservations it intends to observe relating to this participation; and the name and address of its principal competent authority, i.e., its national drug regulatory authority. These notifications are subsequently published in the monthly WHO Pharmaceutical Newsletter and also in WHO Drug Information. A Member State may opt to participate solely for the purpose of importing pharmaceutical products and substances. This intention should then be stated explicitly in its notification. A Member State intending additionally to use the Scheme in connection with the exportation of pharmaceutical products and substances must first satisfy itself that it possesses: an effective national licensing system, not only for pharmaceutical products, but also for the responsible manufacturers and distributors; GMP requirements, consonant with those recommended by WHO, to which all manufacturers of finished pharmaceutical products or licensed pharmaceutical substances are required to conform; effective controls to monitor the quality of pharmaceutical products admitted to the market, including access to an independent quality control laboratory; a national pharmaceuticals inspectorate, operating as an arm of the national drug regulatory authority, that possesses the technical competence, experience and resources to assess whether GMP and other controls are being effectively implemented, and with the powers to conduct appropriate investigations to ensure that manufacturers conform to these requirements by, for example, examining premises and records and taking samples; administrative capacity to issue the required certificates, to institute inquiries in the case of complaint, and to notify expeditiously the competent authority in any Member State known to have imported a specific product that is subsequently associated with a potentially serious quality defect or other hazard. It is for each Member State to determine, through a process of self-evaluation, whether it satisfies these prerequisites. The Scheme contains no provision, under any circumstance, for external inspection or assessment, either of a competent national authority or of a manufacturing facility.
7 WHO Drug Information Vol. 3, No. 3, 1989 General Policy Topics Scope and format of the certificate The certificate transmits information relevant to a specific pharmaceutical product. It is prepared by the competent authority in the country of export ('the certifying authority") upon application by the licenceholder (the applicant") and it is delivered to the competent authority in the importing country ("the requesting authority"). The requesting authority has the option of determining the application for importation exclusively on the basis of the certified information, or of requesting supplementary data from the applicant. The recommended format of the certificate is displayed on page 115. Each product or substance should be identified by: the name by which it is commercially designated and the dosage form; the international nonproprietary name and the amount of each active ingredient; and the name of the manufacturer and, when applicable, the agent responsible for placing the product on the market in the country of export. The attestation provided on the status of the product or substance in the country of export should indicate: whether it has been authorized to be placed on the domestic market and, if not, the reasons why such authorization is lacking; whether the manufacturing plant in which it is produced is subject to inspections at suitable intervals and, if not, the reason why such inspection is not undertaken; that the manufacturer conforms to GMP requirements, as recommended by the WHO; and that the complete text of all labelling and prescribing information authorized for use in the country of export, as submitted by the applicant, is appended to the certificate. In notifying its intention to participate in the Scheme a Member State enters into no commitment to certify supplementary information. Additional certified data, such as a disclosure of the complete qualitative and quantitative formula of the finished dosage form, are thus obtainable only at the discretion of the certifying authority and with the permission of the applicant. Other items that might be added on this basis to satisfy licensing requirements in the importing Member State include information on the date of manufacture, results of analyses, dissolution and bioavailability data, stability data, packaging, shelf-life and any approved technical summary on which the marketing authorization in the country of export is based. In the absence of any specific agreement, each certificate will be prepared exclusively in the working language(s) of the certifying authority. The applicant will be responsible for providing any notarized translation that may be required by the requesting authority. It is recognized that implementation of the Scheme imposes a significant administrative service on certifying authorities. This service may need to be financed by levying a fee on applicants. The certificate refers to products "authorized to be placed on the market" rather than to products that "are sold" in the country of export. Since the certi fying authority can attest only to matters related to its formal responsibilities. Decisions regarding the marketing of duly-licensed products are determined by the applicant. The objective is to establish whether a product licence has been granted with the explicit purpose of authorizing the applicant to place the product on the market in the country of export subject to any conditions that may be applied. Some products may not be authorized for sale in the country of export for reasons that are unconnected with considerations of quality, efficacy and safety. These include: products developed exclusively for the treatment of conditions and particularly tropical diseases not endemic in the country of export. These, when they are not intended for sale and distribution within the country of export, may fall outside the statutory purview of the certifying authority. Even when this is not the case, the certifying authority can exert no influence over the clinical or post-marketing phases of the development of a product that is not used within its jurisdiction. In these circumstances, the requesting authority has the option of turning to the World Health Organization for technical advice. However, it will need assurance from the certifying authority that GMP has been observed in all stages of the manufacture of the product.
8 General Policy Topics WHO Drug Information Vol. 3, No. 3,1989 products that have been reformulated with a view to improving their stability during storage under tropical conditions or to exclude excipients not approved for use in pharmaceutical products in the country of import. These would normally qualify for approval by the certifying authority only after technical review of the implications that the proposed changes might have for the stability and bioavailability of the product and for other aspects of its safety and efficacy, and a statement to this effect should be entered into the certificate. Each certificate is intended to convey information on one product only. This principle has become of greater moment now that exchange of product information has been brought within the ambit of the Scheme. Confusion is liable to arise if information relating to different products, or even different dosage forms, is attached to the same certificate. The approved information for different dosage forms of the same active substance frequently differs substantially particularly with reference to composition, indications and dosage instructions. Notwithstanding these considerations, importing Member States frequently issue international tenders citing large numbers of products and, in doing so, request manufacturers to support their bids with export certificates. Supplying large numbers of detailed certificates in these circumstances would impose an unacceptable administrative burden on the certifying authority and add substantially to the costs of the tendering procedure. In these circumstances, preliminary proof that a valid product licence exists within the exporting country for each of the products cited is all that is usually required. Subject to the agreement of the tendering authority, a single short-form certificate referring to several products might then be issued. As a minimum, this would identify each product in the terms described above, its licence number in the country of export, and the date on which the licence was issued. It would also provide a declaration that a separate and complete certificate for each product will be provided on request. Requesting a certificate A product certificate is a confidential document. As such, it can be prepared only in response to an application by the holder of the product licence (the applicant). An importing agent or a national drug regulatory authority requiring certified information on a product should consequently channel the request through the applicant in the exporting Member State. In the course of issuing an open tender an importing agent may also wish to place bidders on notice that certified evidence of marketing authorization in the country of export will be required as a condition of acceptance of a bid. Clear understandings must be established between the competent national authority and all agents operating under its aegis that hold responsibility for importing drugs into the country, within both the public and the private sectors, on when certificates will be required for licensing purposes. In general terms, the competent authority will require certified information whenever a licensing action is required to provide authorization to import: any product not previously licensed within the country of import, including a multisource product not licensed to be imported from the manufacturer in question. any previously licensed product when, for any reason, administrative action is required to renew, extend, vary or review the existing licence. By formally notifying its participation in the Scheme a Member State signifies its general acceptance that the assurances it provides, together with any additional collated information on the product in question it may require from the applicant, comprise a sufficient basis for it to determine whether the product may be licensed for importation and marketing within its jurisdiction. Only exceptionally should requests for supplementary information be referred to the certifying authority. It is the responsibility of the requesting authority to determine the period during which it will accept certified information as valid. It may wish to impose, as a general condition, a requirement upon the licence holder to submit an updated certificate periodically say, perhaps, at five-year intervals as a condition of extension or renewal of the product licence. The WHO Scheme additionally provides for the certification of specific batches of a product or substance covered by an existing certificate. It indicates that such certificates could be issued either by the manufacturer or by the competent authority of the exporting Member State. However, batch certification is only undertaken exceptionally by the competent national authority, and usually only in relation to vaccines and other biologicals. For other
9 WHO Drug Information Vol. 3, No. 3, 1989 General Policy Topics products, responsibility for batch certification, including assurance of compliance with pharmaco poeial or other specifications, and of the expiry date under specified storage conditions, devolves upon the applicant and the importing agent, subject to any conditions imposed by the requesting authority. The attestation regarding compliance with GMP should be provided only when the certifying authority has ascertained, to its satisfaction, which stages of the manufacturing operations are undertaken in the premises that have been subjected to inspection. The practice of purchasing multisource (i.e. generic) products or substances in response to bids received on open tender holds particular implications for the certification procedure. Whenever a product is purchased through a broker or another intermediary, or when more than one set of premises has been involved in the manufacture and packaging of a product, certified documentation should be provided from the competent authorities in each of the countries involved, variously, in the manufacture, assembly, packaging, repackaging, relabelling (to give it a new designation), or transshipment of the product, in a way that reliably establishes its "pedigree". Issuing a certificate Responsibility for the authenticity of the data contained in a certificate issued in conformity with the Scheme is assumed by the certifying authority. Certificates will not bear the emblem of the World Health Organization, but a statement should always be included to confirm that the document is issued in the format recommended by WHO. When such confirmation cannot be supplied the reasons should be stated. In general, certificates will be issued on the basis of data contained in the current version of the product licence. The certificate should accordingly indicate the date on which the information supplied was established to be correct. This will reflect the occasion on which the product licence was most recently reviewed. In particular, every effort should be made to indicate the dates on which: the manufacturing facility was last inspected; the product information was last reviewed. ft should be recognized that GMP assigns responsibility for assuring the quality of starting materials on the manufacturer of the final dosage forms. Many competent authorities, none the less, require the anticipated manufacturers of starting materials to be specified in the product licence. As a matter of policy, the competent authority may neither inspect manufacturers of starting materials nor license their products or, should it do so, it may limit such inspections to selected active ingredients. Notwithstanding this situation, a certifying authority may agree, on a discretionary and voluntary basis, and at the request of a manufacturer, to undertake an inspection of a manufacturer of starting materials to satisfy specific requirements of a requesting authority. Alternatively, the certifying authority may be able to attest that the manufacturer is an established supplier of the substance in question to manufacturers of finished dosage forms licensed for marketing under its jurisdiction. Whenever possible, international nonproprietary names, as selected by the World Health Organization, should be employed to identify active ingredients. A declaration that a product has been authorized to be placed on the market should be qualified, whenever applicable, by any restriction upon its sale, distribution or administration that is entered into the product licence. In many countries, some long-established products still remain on the market on the basis of provisional licensing arrangements. These have not been subjected to full technical assessment in accordance with contemporary statutory requirements. Certified information relating to such products should indicate clearly in what respects statutorily-required review remains pending. In certifying that the manufacturing facility is subject to inspection at suitable intervals and that the manufacturer conforms to WHO recommendations on GMP, it should be ascertained: to what extent the manufacturing facility in question has contributed to the production of the finished dosage form, including its labelling and packaging; that the inspectorate has satisfied itself that the manufacturer is implementing, in all material respects, recommendations specifically applicable to biological products that have been adopted by the WHO Expert Committee on Biological Standardization and other WHO expert groups as published in the WHO Technical Report Series;
10 General Policy Topics WHO Drug Information Vol. 3, No. 3, 1989 that the same norms are applied to the production of all batches of pharmaceutical products manufactured within the facility, including those destined exclusively for export; that the applicant consents to relevant inspection reports being released, in confidence, to the competent authority in the country of import, should the latter so require, together with the names and functions of the persons within the company designated to sign certificates of individual batches of the product to be exported, and information on any independent controls exercised by the competent authority, as a condition of marketing, on batches of the product prior to their release. In those instances in which more than one company contributes to the production of a finished dosage form the certificate should either: provide separate attestations to cover those aspects of manufacture undertaken by each of the interested parties; or identify those aspects of the manufacturing operation for which no attestation can be provided. Because of the administrative workload involved, it may not always be feasible for the certifying authority to attest that copies of information and labelling submitted to it by an applicant in support of a request for a certificate are consonant, in every particular, with the conditions of the relevant product licence. In these circumstances, the only practicable recourse for the certifying authority may be to stamp each of these documents as having been submitted to it on a given date in support of an application for a certificate. Every effort should be taken, however, to ensure, by inspection, that the information is complete, particularly in respect of indications for use, dosage instructions, precautions and contraindications. In the event of any apparent deficiency or discrepancy, certification should be held in abeyance pending clarification and satisfactory resolution of the matter by the applicant. The requesting authority should also check, as far as is practicable, that these accord with any officially-approved product information contained in published compendia used within the country of export, which are supplied to the national information officers under the aegis of WHO. Any attachment to a certificate, including dulystamped product information or price lists of products for which bids are offered, should be clearly identified as not comprising part of the attestation made by the certifying authority. To avert potential abuse of the Scheme and to enable the certifying authority to maintain comprehensive records of countries to which specific products have been exported, each certificate should identify the requesting authority, be stamped on each page with the official seal of the certifying authority and be issued directly to the requesting authority. Copies provided to applicants should bear no official seal and be clearly marked as duplicates. Notifying and investigating a quality defect Each participating Member State undertakes to institute enquiries into any quality defect reported in a product or substance exported in accordance with the provisions of the Scheme, on the understanding that: the complaint is transmitted, together with the relevant facts, through the competent authority in the country of import; the complaint is considered to be of a serious nature by the latter authority; and the defect, if it appeared after the delivery of the batch in question into the importing Member State, is not attributable to local conditions. Conversely, each certifying authority undertakes to inform the competent authorities in countries that have imported a product under the provisions of the Scheme of any serious hazards subsequently associated with its use when such a product has been distributed internationally. The certifying authority will execute this responsibility by issuing an appropriate warning to the World Health Organization of the defect, through the officially-designated information officer, for relaying to all Member States. The World Health Organization stands prepared to offer advice and particularly to identify a quality control laboratory disposed to undertake independent analytical tests should difficulty arise in resolving a complaint, but it cannot engage in any consequential litigation or arbitration.
REGULATION (EEC) No 2309/93
REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary useMore information
January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposalMore information
Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 ofMore information
Criteria for Medicinal Drug Promotion
Criteria for Medicinal Drug Promotion Introduction 1. Following the WHO Conference of Experts on the Rational Use of Drugs held in Nairobi in November 1985, WHO prepared a revised drug strategy which wasMore information
Annex 9 Guide to good storage practices for pharmaceuticals 1
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilitiesMore information
SADC GUIDELINES ON IMPORT AND EXPORT PROCEDURES FOR PHARMACEUTICAL PRODUCTS June 2006 1 INTRODUCTION Public health concerns demand that the manufacture of pharmaceutical products and their subsequent handlingMore information
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoptionMore information
Annex 7 Guidelines on pre-approval inspections
World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for theMore information
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at anyMore information
INITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has beenMore information
FINAL DOCUMENT. Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers Part 1: General Requirements
GHTF/SG4/N28R4:2008 FINAL DOCUMENT Title: Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers Authoring Group: GHTF Study Group 4 Endorsed by: The Global HarmonizationMore information
DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Steps taken after authorisation summary Page 12 Summary ofMore information
5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)More information
Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs
Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminarMore information
Guideline on dossier requirements for Type IA and IB notifications
Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variationsMore information
Standards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the lawMore information
Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical TrialsMore information
Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR
Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken forMore information
1 11 MEDICATION MANAGEMENT OVERVIEW OF MEDICATION MANAGEMENT Depending on the size, structure and functions of the health facility, there may be a pharmacy with qualified pharmacists to dispense medication,More information
ARIZONA. Downloaded January 2011
ARIZONA Downloaded January 2011 R9 10 101. DEFINITIONS 24. "Health care institution" means every place, institution, building or agency, whether organized for profit or not, which provides facilities withMore information
Insurance and compensation in the event of injury in Phase I clinical trials
Insurance and compensation in the event of injury in Phase I clinical trials Guidance developed by the Association for the British Pharmaceutical Industry, the BioIndustry Association and the ClinicalMore information
Annex II. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation
Annex II Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation 7 Scientific conclusions Overall summary of the scientific evaluation of Cymevene i.v. and associatedMore information
Site visit inspection report on compliance with HTA minimum standards. Belfast Cord Blood Bank. HTA licensing number 11077.
Site visit inspection report on compliance with HTA minimum standards Belfast Cord Blood Bank HTA licensing number 11077 Licensed for the procurement, processing, testing, storage, distribution and import/exportMore information
Risk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, LabourMore information
Importing pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approvalMore information
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP complianceMore information
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing MedicinalMore information
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and HealthcareMore information
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,More information
Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug TransferMore information
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.More information
OVERVIEW OF THE PREQUALIFICATION OF DIAGNOSTICS ASSESSMENT PROCESS. Prequalification of Diagnostics
D i a g n o s t i c s a n d L a b o r a t o r y T e c h n o l o g y OVERVIEW OF THE PREQUALIFICATION OF DIAGNOSTICS ASSESSMENT PROCESS Prequalification of Diagnostics PQDx_007 v3 20 April 2010 Table ofMore information
Annex 3 Procedure for prequalification of pharmaceutical products
World Health Organization WHO Technical Report Series, No. 953, 2009 Annex 3 Procedure for prequalification of pharmaceutical products 1. Introduction 2. Glossary 3. Purpose and principles 4. Steps ofMore information
Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof,
L 121/34 DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating toMore information
SMF Awareness Seminar 2014
SMF Awareness Seminar 2014 Clinical Evaluation for In Vitro Diagnostic Medical Devices Dr Jiang Naxin Health Sciences Authority Medical Device Branch 1 In vitro diagnostic product means Definition of IVDMore information
Session 5. Pharmaceutical Quality Assurance
Drug and Therapeutics Committee Training Course Session 5. Pharmaceutical Quality Assurance Participants Guide Drug and Therapeutics Committee Training Course Participants Guide This document was madeMore information
Clinical Trial Compensation Guidelines
Clinical Trial Compensation Guidelines Preface These guidelines contain two distinct sections: Phase I Clinical Trials Compensation Guidelines Phases II, III and IV Clinical Trials Compensation GuidelinesMore information
Annex 10 Procedure for prequalification of pharmaceutical products
World Health Organization WHO Technical Report Series, No. 961, 2011 Annex 10 Procedure for prequalification of pharmaceutical products 1. Introduction 2. Glossary 3. Purpose and principles 4. Steps ofMore information
April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:More information
AGREEMENT ON TECHNICAL BARRIERS TO TRADE. Having regard to the Uruguay Round of Multilateral Trade Negotiations;
Page 117 AGREEMENT ON TECHNICAL BARRIERS TO TRADE Members, Having regard to the Uruguay Round of Multilateral Trade Negotiations; Desiring to further the objectives of GATT 1994; Recognizing the importantMore information
Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood
Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood Supreme Council of Health Department of Research Guidance Regarding Research Involving Human EmbryonicMore information
Administrative Policies and Procedures for MOH hospitals /PHC Centers. TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide
Administrative Policies and Procedures for MOH hospitals /PHC Centers TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide NO. OF PAGES: ORIGINAL DATE: REVISION DATE : السیاساتMore information
Introduction 2. 1. The Role of Pharmacy Within a NHS Trust 3. 2. Pharmacy Staff 4. 3. Pharmacy Facilities 5. 4. Pharmacy and Resources 6
Index Index Section Page Introduction 2 1. The Role of Pharmacy Within a NHS Trust 3 2. Pharmacy Staff 4 3. Pharmacy Facilities 5 4. Pharmacy and Resources 6 5. Prescription Charges 7 6. CommunicationMore information
NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatientMore information
This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2001L0020 EN 07.08.2009 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENTMore information
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EECMore information
Guide to Fees for Veterinary Products
Guide to Fees for Veterinary Products FIN-G0003-14 04 FEBRUARY 2016 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONSMore information
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislationMore information
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refersMore information
IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure toMore information
Professional Standards and Guidance for the Sale and Supply of Medicines
Professional Standards and Guidance for the Sale and Supply of Medicines About this document The Code of Ethics sets out seven principles of ethical practice that you must follow as a pharmacist or pharmacyMore information
4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of ClinicalMore information
Population Health Management Program
Population Health Management Program Program (formerly Disease Management) is dedicated to improving our members health and quality of life. Our Population Health Management Programs aim to improve careMore information
The Basics of Drug Resistance:
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) firstname.lastname@example.com The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?More information
PRIORITY RESEARCH TOPICS Understanding all the issues associated with antimicrobial resistance is probably impossible, but it is clear that there are a number of key issues about which we need more information.More information
Regulation and Risk Management of Combination Products
Regulation and Risk Management of Combination Products Katherine Ulman Associate Scientist Global Regulatory Compliance Manager Dow Corning Healthcare Jim Curtis Senior Specialist, Healthcare ApplicationsMore information
NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997
NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997 Plenary of the National Health Council in its 15 th Special Meeting, held on 5 August 1997, in the exercise of its competencies, as set forthMore information
MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the DrugsMore information
Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs)
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal ProductsMore information
3BC6a RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE Guideline Title Rapid Alert System (RAS) in Pharmacovigilance Legislative basis Directive 65/65/EEC as amended, Council Regulation 2309/93 Date of firstMore information
Terms and Conditions of Offer and Contract (Works & Services) Conditions of Offer
Conditions of Offer A1 The offer documents comprise the offer form, letter of invitation to offer (if any), these Conditions of Offer and Conditions of Contract (Works & Services), the Working with QueenslandMore information
National Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Effective January 1, 2015 Goal 1 Improve the accuracy of resident identification. NPSG.01.01.01 Long Term are ccreditation Program Medicare/Medicaid ertification-based OptionMore information
Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0
Guideline Treatment of tuberculosis in patients with HIV co-infection Version 3.0 Key critical points Co-infection with Tuberculosis (TB) and HIV is common in many parts of the world, especially sub-saharanMore information
EMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency ofMore information
Public Cord Blood Bank
The The Public Cord Blood Bank Page 1 of 21 TABLE OF CONTENTS INTRODUCTION... 3 WHAT ARE GOOD MANUFACTURING PRACTICES?... 5 1 TOTAL QUALITY... 7 2 PREMISES... 8 3 EQUIPMENT AND MATERIAL... 9 4 PERSONNEL...More information
WHEREAS updates are required to the Compensation Plan for Pharmacy Services;
M.O. 23/2014 WHEREAS the Minister of Health is authorized pursuant to section 16 of the Regional Health Authorities Act to provide or arrange for the provision of health services in any area of AlbertaMore information
Investigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in placeMore information
Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remainsMore information
GUIDELINES FOR FOOD IMPORT CONTROL SYSTEMS SECTION 1 SCOPE CAC/GL 47-2003 1. This document provides a framework for the development and operation of an import control system to protect consumers and facilitateMore information
Draft guidance for registered pharmacies preparing unlicensed medicines
Draft guidance for registered pharmacies preparing unlicensed medicines January 2014 1 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmaciesMore information
N.B Unofficial translation, legally binding only in Finnish and Swedish MINISTRY OF SOCIAL AFFAIRS AND HEALTH, FINLAND
N.B Unofficial translation, legally binding only in Finnish and Swedish MINISTRY OF SOCIAL AFFAIRS AND HEALTH, FINLAND No. 101/2001 Act on the Medical Use of Human Organs, Tissues and Cells (AmendmentsMore information
Health Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 3 Residential Care Facilities and Homes Standards of Practice Table of Contents 1. Application 2. Definitions 3. Supervision of Pharmacy Services in a FacilityMore information
Page 1 AFRICAN UNION UNION AFRICAINE UNIÃO AFRICANA Addis Ababa, ETHIOPIA P. O. Box 3243 Telephone 251-11-5517 700 Fax 251-11-5517 844 website: www. africa-union.org 5 th SESSION OF THE AU CONFERENCE OFMore information
AUSTRALIAN MEDICAL DEVICES GUIDELINES Transitional Arrangements for the Introduction of the New Medical Devices Regulatory System Guidance Document Number 9 Version 1.6 DISCLAIMER This document is providedMore information
REGULATIONS FOR THE DEGREE OF BACHELOR OF PHARMACY IN CHINESE MEDICINE [PART-TIME] (BPharm[ChinMed])
REGULATIONS FOR THE DEGREE OF BACHELOR OF PHARMACY IN CHINESE MEDICINE [PART-TIME] (BPharm[ChinMed]) These regulations apply to students admitted to the first year of study in and after the academic yearMore information
Annex 6. Guidance on variations to a prequalified product dossier. Preface
Annex 6 Guidance on variations to a prequalified product dossier Preface This guidance document was technically and structurally inspired by the Guideline on dossier requirements for type IA and IB notifiMore information
EXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES Introduction The WHO Prequalification of Medicines Programme (PQP) was established to provide UNMore information
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( HealthMore information
Severe Combined Immune Deficiency (SCID)
Severe Combined Immune Deficiency (SCID) ASCIA EDUCATION RESOURCES (AER) PATIENT INFORMATION Severe combined immune deficiency (SCID) is the most serious form of primary immune deficiency and is usuallyMore information
PG Certificate / PG Diploma / MSc in Clinical Pharmacy
PG Certificate / PG Diploma / MSc in Clinical Pharmacy Programme Information September 2014 Entry School of Pharmacy Queen s University Belfast Queen s University Belfast - Clinical Pharmacy programmeMore information
4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group andMore information
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIESMore information
ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALSMore information
Official Journal of the European Union. (Acts whose publication is obligatory)
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amendingMore information
National Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Goal 1 Nursing are enter ccreditation Program Improve the accuracy of patient and resident identification. NPSG.01.01.01 Use at least two patient or resident identifiers whenMore information
Frequently Asked Questions (FAQs)
Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducingMore information
CICLOSPORIN. What are the aims of this leaflet?
CICLOSPORIN What are the aims of this leaflet? This leaflet has been written to help you understand more about ciclosporin. It tells you what it is, how it works, how it is used to treat skin conditions,More information
Annex 2. WHO good manufacturing practices for pharmaceutical products: main principles 1
Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles 1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy andMore information
The Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-More information
Page 191 TITLE 21 FOOD AND DRUGS 355 1
Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken priorMore information
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Linezolid 2 mg/ml solution for infusion Linezolid 600mg film coated tablets Linezolid 100mg/5ml granules for oral suspension Procedure No: UK Licence No:More information
Pharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19thMore information
Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\AnnexMore information
Medical Questionnaire and Informed Consent Public Cord Blood Bank Switzerland
Medical Questionnaire and Informed Consent Public Cord Blood Bank Switzerland You have just read the information sheet for cord blood donors and you would like to donate cord blood. We thank you for answeringMore information
Ethical criteria for medicinal drug promotion
Ethical criteria for medicinal drug promotion World Health Organization Geneva 1988 ISBN 92 4 154239 X O World Health Oganbatian, 1988 Publications of the World Health Organization enjoy copytight protectionMore information
Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products
Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products U.S. Department of Health and Human Services Food and Drug AdministrationMore information
Pre-market Information - Class III and IV
Pre-market Information - Class III and IV Life Sciences Council British Columbia NRC Industry Research Assistance Program Vancouver, October 29, 2007 Mary-Jane Bell, Ph.D. Medical Devices Bureau (MDB)More information
Sarah Chandler A/Head, Regulatory and Scientific Section Medical Devices Bureau firstname.lastname@example.com
Software Regulated as a Medical Device Sarah Chandler A/Head, Regulatory and Scientific Section Medical Devices Bureau email@example.com Therapeutic Products Directorate Director General S. SharmaMore information
Hong Kong Guide to Good Manufacturing Practice for the Secondary Packaging of Pharmaceutical Products
Hong Kong Guide to Good Manufacturing Practice for the Secondary Packaging of Pharmaceutical Products Version 1.3 Drug Office, Department of Health. Contents list 1. QUALITY MANAGEMENT... 4 2. PERSONNEL...More information
Prescribing for patients with asthma by general practitioners in England and Wales
Prescribing for patients with asthma by general practitioners in England and Wales 1994 96 Azeem Majeed and Kath Moser, ONS The objective of this study was to examine trends in the management of asthmaMore information


text:
Disclaimer: As of this writing, I have not played Gran Turismo 6 but I did order it a couple of days ago and it's on the way. Everything written from here on is based on the impression I have gotten from reviewers and people who have played the game. So, …Read More »
Home / Tag Archives: Kazunori Yamauchi


text:
Brayden Point was absolutely dominant on Tuesday night, helping Canada skate to a 7-1 win over the Czech Republic at the World Junior Summer Showcase.
Canada was definetly not the stronger team in the first period. Trying to play a more physical game than their opponents, Canada spent a little too much time trying to knock down opposing Czech forwards than creating scoring chances. It led to the Czech's getting many scoring chances right off the bat, forcing Mackenzie Blackwood to be busy early on. He'd face 10 shots in the first 15 minutes of the game, while Washington Capitals prospect Vitek Vanecek only needed to deflect five away in the early going.
Canada's lazy attempts to get the puck out of their own zone would end up hurting them. At 11:38 into the opening frame, future Carolina Hurricanes defensemen Haydn Fleury and Roland McKeown struggled to find their place in front of the Canadian net, allowing Filip Chlapik to skate in and fire a quick wrist shot to make it 1-0. It was the second time in two nights that Canada would allow the first goal of the game, seeing the exact same thing happen with their other roster against Russia on Monday night. It was a definetly a slow start for the second Canadian roster, using players that didn't participate in Monday's showing.
With 1:15 left in the opening period, Canada found a way to tie the game up at one apiece. Jake Virtanen, a solid power-forward that showed some big skill early in the contest, skated in to the Czech zone before making a quick spin to find Rourke Chartier. The San Jose Sharks prospect was in a perfect position to get a shot on net, firing it from outside the slot to knot it up at one heading into the first intermission.
Canada came out a little stronger in the second, and before the period was even five minutes old, they were able to take the 2-1 lead. Brayden Point, a Tampa Bay Lightning prospect who fought his way onto the team last year, was the mastermind behind the play, skating through the offensive zone before sending a quick pass over to Jake Virtanen, who one-timed it into the back of the net to make it 2-1 Canada.
With 5:16 off the score clock in the second, Canada had a two goal advantage. This time, Haydn Fleury took a pass from Travis Konecny along the boards before firing a nifty wrist shot under Vitek Vanecek's blocker and in to make it 3-1.
Konecny and Point were both having strong nights, dominating the offensive zone every time they got ahold of the puck. Some slick passing between the pair, mixed with some incredible hockey IQ, eventually saw Konecny find Point skating near the doorstep, firing a quick pass over before Point found the back of the net to make it 4-1 Canada with seven minutes to go.
Point's second period dominance wasn't complete in the second period. After a pass from Konecny at Canada's goal line went up the ice, Point skated up the ice before sending the puck over to Brandon Hickey, who tapped the puck in just in front of the net to give Canada the 5-1 lead. Point was used mainly as a bottom six player for Canada last year, but did see some action on the first two lines after injuries played a role near the end. For Tampa Bay, Point's another young, small, talented forward with a ton of upside in the system, similar to what Tyler Johnson brings to the club already.
Canada's one-way dominance on the score sheet would continue early in the second. After 4:30 of play, Virtanen got his second of the night after Connor Bleackley found the Canucks prospect streaking before Virtanen ripped it over the glove of Vanecek. With seven minutes to go in the game, Konecny would find Point once again in front of the net, with the Lightning prospect scoring on a gift play to make it 7-1 Canada. It was the final marker in a game that really fell apart for the Czech's, who would drop a 7-1 decision to Canada to keep the home team undefeated for a second day.
Canada will spend the time before the game tomorrow at 10pm EST time against Russia to determine a roster for the final two games of the mini-tournament. The expectation is that Florida Panthers prospect Samuel Montembeault will man the pipes on Wednesday, a chance for Canada to go 3-0 in their own tournament.
Follow me on twitter, @StevenEllisNHL.


text:
The bubbles are floating
Playing in the sky
Some fun
Some are colourful
Sun shining through them.
By Sahib
Bubbles landing
Blue shining colours
In the air
By Alejandro
I saw the bubbles
Floating in the air
They reached to the floor
I saw some more
The colours were blue
Green purple pink and yellow
By Caleb
Dip your pipe
And gently blow,
Watch the tiny bubbles grow,
Bigger and bigger
Round and fat
Rainbow colours
And then splat!!
By Diya


text:
It has only been two weeks since the successful Kickstarter campaign of the ARKYD space telescope, and I have already come across another promising proposal. And let me say this right at the beginning: I have donated the largest sum of money to this project among all the ones I have supported, and by a huge margin. I have two reasons for it. First and foremost, I think this idea is worth our attention and support, and I will explain why shortly. Secondly, unlike ARKYD where you had a campaign backed by considerable media attention—most likely due to the group of influential people in the board of Planetary Resources—this project is really down to earth; just a few university professors who want to make their dream a reality. And since I tend to sympathise with that dream, I am willing to risk my money in hope it will one day become a reality, and I hope that after explaining this idea, at least some of you will follow suit.
First, let us discuss what cubesats are, as they are what drive this Kickstarter campaign. In short, cubesats are nano satellites built by using off-the-shelf components, and launched to space by basically piggybacking other, usually governmental, primary payloads. They are relatively low-cost, allowing non governmental agencies, such as universities, to do space research without spending millions of dollars on it. All this, however, comes with a price. Since cubesats get to space as secondary, non-essential payloads, they have strict requirements regarding size and weight. Cubesat are measured in units, where one unit is a 10x10x10 centimeter cube—hence the name—with a weight limit of 1.33 kilograms. Although cubesats can be up to 3 units large, therefore allowing them to perform quite complicated missions, up until now they all lacked one important component: propulsion. Cubesats are put into a low Earth orbit and usually drift there until they eventually burn up in the atmosphere, usually within a few years. They are inherently trapped in Earth orbit, and that is what this Kickstarter campaign would like to remedy.
A group of scientists at the University of Michigan believe to be able to engineer a small, plasma engine, called the CAT—CubeSat Ambipolar Thruster—that could potentially enable cubesats in the future to escape Earth's gravity and enter interplanetary, and even extrasolar space. This is a domain that, up until now, belonged to only the most robust and successful government programs. With the promise of the CAT engine, however, universities, schools, basically anyone with a small to modest investment will be able to send small satellites beyond Earth; to Mars, to Saturn, and beyond; the opportunities are limitless. I think this is a huge deal, and if this Kickstarter has even the slightest chance to make mobile cubesats a reality, I am willing to risk my money by supporting it, and I urge you to follow suit. It is a worthy and very exciting cause. If you wish to take a closer look, here is the link to the Kickstarter Campaign


text:
"There is no worse robber than a bad book."
This is a popular Italian proverb, which might lead you to wonder what other interesting expressions the Italians have up their sleeves. Here are a few...
"La gatta frettolosa ha fatto i gattini ciechi."
"The hurried she-cat has made blind kittens."
"La madre degli idioti è sempre incinta."
"The mother of idiots is always pregnant."
"La vita è come un albero di natale, c'è sempre qualcuno che rompe le palle."
"Life is like a Christmas tree, there's always someone who breaks the balls."
"Il bene del matrimonio dura tre die - il male dura fino a la morte."
"The good of the marriage lasts three days - and the bad lasts til death."
"Se si disperdono spine, non camminare scalzi."
If you scatter thorns, don't go barefoot.
"Al contadino non far sapere quanto è buono il cacio con le pere."
"Don't tell a peasant how well cheese goes with pears."
... and the rather intriguing:
Per un punto, Martin perse la cappa!"
"Because of a period, Martin lost his post!"
This last proverb has its roots in a tale of an acolyte monk by the name of Martin who was told to write the Latin phrase "Porta patens esto. Nulli claudatur honesto" ("Be the door always open. Be not closed to any honest person") in reference to the doors of the monastary. Unfortunately, poor old Martin wrote "Porta patens esto nulli. Claudatur honesto." ("Be the door open to no one. Be it closed to honest people."), and thus lost his right to become a monk.
This quote & biography originally ran in an issue of BookBrowse's membership magazine. Full Membership Features & Benefits.
The 7 ½ Deaths of
Evelyn Hardcastle
"Agatha Christie meets Groundhog Day...quite unlike anything I've ever read." - A. J. Finn
The Big Holiday Wordplay: $400+ in Prizes
Visitors can view some of BookBrowse for free. Full access is for members only.
Your guide toexceptional books
BookBrowse seeks out and recommends books that we believe to be best in class. Books that will whisk you to faraway places and times, that will expand your mind and challenge you -- the kinds of books you just can't wait to tell your friends about.


text:
Dr. Kristina Janssen Donovan is a physiatrist specializing in physical medicine and rehabilitation. She focuses on the diagnosis and treatment of orthopaedic conditions utilizing a nonsurgical approach including medications, physical therapy, and muscle and joint injections. She also performs spinal injections including lumbar epidural steroid injections, caudal epidural injections, lumbar facet and medial branch blocks, and sacroiliac joint injections. She also received specialized training in the diagnosis of neuromuscular disorders and performs EMGs and nerve conduction studies.
Dr. Donovan joined the SportsMED team in 2012 after completing her physical medicine and rehabilitation residency at UAB. There she was chief resident and recipient of the PM&R 2012 Huang Risident Award for Clinical Excellence. Dr. Donovan graduated cum laude from Marshall University with an undergraduate degree in Biology. She then attended the West Virginia School of Osteopathic Medicine followed by an internal medicine internship at the University of Louisville.
Dr. Donovan conducted and participated in several clinical research studies on topics ranging from traumatic spinal cord injuries to outcomes of
Specialty Centers: Physiatry


text:
We learned this weekend that our friend and ally, Diane Duke, CEO of one the one of the industry's vital organizations the Free Speech Coalition, is resigning. You can read more about her in this XBIZ story.
She has been a longtime tireless advocate for the industry, and has fought to protect performers and businesses alike from attack campaigns and attempts to eliminate the rights of freedom of speech and expression.
We will miss her in her leadership role with FSC, but we know that this is not the last we have heard from Diane.
CCBill wishes her every success in her next venture.


text:
Democrats claim their sweeping financial-sector reforms will guard against the kind of problems that triggered the recent economic meltdown. But if they really wanted to do that, they would've focused on how so many US officials were simply . . . bought. Fat chance.
Nonetheless, Rep. Darrell Issa (R-Calif.), ranking member of the House Committee on Oversight and Governmental Reform, is demanding just such a review — and, for the sake of the nation, he should get one.
Last week, Issa wrote to Alfred Pollard, general counsel to the Federal Housing Finance Agency, which oversees Fannie Mae and Freddie Mac, asking for a probe of "VIP" mortgage loans given to Fannie and Freddie executives by Countrywide Financial Corporation. He also disclosed that Senate staffers got 30 low-rate mortgages under the program.
Founder Angelo Mozilo built Countrywide into the nation's largest mortgage lender, with a portfolio at one point worth $1.4 trillion, by selling billions in mostly subprime loans to Fannie and Freddie. Clinton Attorney General Janet Reno, using the anti-redlining statute — the Community Reinvestment Act — relentlessly pressured banks to make loans to "the underserved." But the banks could not make enough subprime mortgage loans to satisfy our lawmakers unless the federal government bought the loans they originated. That's where Fannie and Freddie came in.
Eventually, Congress and the Department of Housing and Urban Development ordered Fannie to spend 50 cents of every dollar buying subprime loans. Today, Fannie and Freddie are wards of the state and own, or are responsible for, $5.5 trillion worth of mortgages.
Documents strongly suggest that, through a VIP loan program at Countrywide for "Friends of Angelo," Mozilo helped spur officials to keep up Fannie and Freddie's multitrillion-dollar mortgage-spending spree and, especially, buying Countrywide's junk mortgages. Special account executives were hired to administer the "FOA" loan program. Their business cards contained the designation "VIP Loan Program," so that the VIPs who received these discounted loans would know they were being given special treatment. Thousands of dollars were saved by each VIP borrower, and each had to have known it.
"Friends of Angelo" loans went to Sen. Chris Dodd (D-Conn.), the Senate Banking Committee chairman; Sen. Kent Conrad (D-N.D.), Budget Committee chairman and a Finance Committee member; Secretary of Housing and Urban Development Alphonso Jackson; Jim Johnson, a former Fannie CEO and adviser to candidate Barack Obama; Clinton Jones III, senior counsel to the House Financial Services Subcommittee on Housing, and Franklin Raines, since-disgraced Fannie CEO.
But the more than 44,000 documents subpoenaed by Issa showed that the corruption in the system ran even deeper. They show that a staggering 153 VIP loans were extended to the quasi-governmental employees who decided what loans Fannie would buy with the taxpayers' money. Another 20 VIP loans were made to Freddie Mac executives.
Mozilo's seemingly systematic efforts to sway lawmakers, a cabinet member, White House staff and the executives at Fannie and Freddie appear to have paid off. In 2007, Countrywide alone originated 23 percent of a massive volume of Fannie and Freddie's mortgage purchases. In that year alone, Mozilo made more than $140 million. VIP borrower and Fannie CEO Jim Johnson signed a strategic agreement with Countrywide granting Fannie exclusive access to Countrywide's junk loans. Mozilo, in effect, had managed to make the United States and Countrywide joint venturers in the most prodigious — and dangerous — subprime-mortgage operation in our country's history.
Mozilo also seems to have stifled numerous bills in Congress aimed at reform — despite warnings by Republicans that a failure to rein in Fannie and Freddie posed grave dangers to taxpayers. When Sen. Richard Shelby (R-Ala.) pushed for a comprehensive fix, Dodd successfully threatened a filibuster.
Meanwhile, despite ethical codes governing Congress, the Executive Branch and Fannie and Freddie, which ban the acceptance of gifts or discounts, influential "Friends of Angelo" accepted their discounted loans.
If House Leader Nancy Pelosi really were interested in reform and in "draining the swamp," she'd have launched a probe long ago. She didn't. Even worse, two-time VIP loan recipient Dodd served as sponsor of the financial-reform law, which makes no effort to deal with Fannie and Freddie, even though to date they've received $145 billion in taxpayer bailouts — with no end in sight.
President Obama and his fellow Democrats singled out Wall Street in their massive reform package. They should have looked in the mirror first.
Stephen B. Meister is a partner in Meister Seelig & Fein LLP.


text:
Subcultures, the popular three tier design from JConcepts, are now available in the popular 2.8" bead mounting diameter. The 2.8" bead-size is used on the popular Traxxas line of vehicles including the Stampede, Stampede 4x4, Rustler and Jato vehicles. The JConcepts design conveniently matches the Traxxas standardized design and is interchangeable back and forth between all Traxxas 2.8" wheels and tires. With JConcepts, a high performance option is now available. The JConcepts design team started from the ground-up with an all new tire design. Designed around a large diameter tire body carcass the Subcultures have the size to take on just about any condition found in the outdoors while giving the vehicle an unmatched visual presence and aggressive stance.
Leaving no detail untouched, the Subcultures carry a beefed up version of the racing inspired 3-tier tread design and configuration giving users a level of performance that was previously unheard of.
It's a whole new world down within the tread as the Subcultures are the first 2.8" tire with three-tier lug technology. The precisely spaced pyramid shaped tread provides the initial feel and control for hard packed, loose and loamy conditions while the step base give the necessary height for wet and soft conditions. At the very base of the Subcultures is a mesh of tread which provides grip at a time when most tires are left bald. Available in soft blue compound, the Subcultures are a specialty tire that when matched to the appropriate conditions can provide the performance and all-around tire that enthusiasts dream of.
The 2.8" Subcultures provide elements that combine light-weight, performance and durability with the inclusion of Profiled closed cell inserts. The highly successful insert material made it's fame on the 1/8th off-road racing circuit and now into the JConcepts 2.8" line. Feel at ease while doing high-speed runs with the durability and performance of the closed cell material which provides durability and feel when others run short.
One large diameter all-terrain tire body profile with hefty Subcultures tread, together with the durable Profiled closed cell inserts has revolutionized tires for the most popular assortment of vehicles on the market. JConcepts is World Proven Innovation and Design.


text:
Posted by Nanaimo District Lacrosse Association on Feb 19 2018 at 11:55AM PST
Midget Evaluations for this evening are cancelled due to the two inches of ice on the box!
Please check the website and/or facebook daily – our head coach is diligently looking at rescheduling and planning on how to get things organized and complete.
Updates will happen as information is available – we appreciate your patience and understanding as Mother Nature apparently isn't a lax fan! We will not be replying to private messages regarding reschedules and we assure you everything will be posted as available!
There are no comments for this announcement.


text:
My husband Jake and I were blessed to be able to adopt Pappy (named Kendall on the website). Chuck and Barb Hickey were his foster parents. They did a wonderful job with him. He is such a sweet boy. He and our 3.5 year old Golden, Murphy, have hit it off well. Pappy kind of does what he wants, and Murphy respects his elders. Pappy is 10 years old. We just love the senior dogs. I know
they aren't always the first chosen when it comes to adopting, but having Pappy in our family brings us so much joy for however long we are lucky enough to have him.
Christina, Jake, Murphy, and Pappy Church


text:
Stuart Robson
What a great article. :o)
A detailed explanation of how it works rather than leaving the lazy dev to copy and paste the code should help us all learn more.
Thanks for writing not only the what's and the how's but also the why's and (importantly) the why not's.
@24Ways that's 16 out of 16, you're on fire!!